Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-miR-26a-5p | ABCB9 | -0.13 | 0.44003 | 1.12 | 0 | miRNAWalker2 validate | -0.32 | 0 | NA | |
| 2 | hsa-miR-26a-5p | ACOT11 | -0.13 | 0.44003 | 1.18 | 0 | mirMAP | -0.18 | 0.01305 | NA | |
| 3 | hsa-miR-26a-5p | ACTR3B | -0.13 | 0.44003 | 0.78 | 0 | miRNATAP | -0.23 | 0 | NA | |
| 4 | hsa-miR-26a-5p | ADAM12 | -0.13 | 0.44003 | 2.41 | 0 | mirMAP; miRNATAP | -0.51 | 2.0E-5 | NA | |
| 5 | hsa-miR-26a-5p | ADM | -0.13 | 0.44003 | -0.33 | 0.31881 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.36 | 0.00018 | NA | |
| 6 | hsa-miR-26a-5p | AKIRIN1 | -0.13 | 0.44003 | -0.01 | 0.95575 | miRNATAP | -0.12 | 6.0E-5 | NA | |
| 7 | hsa-miR-26a-5p | ANKIB1 | -0.13 | 0.44003 | 0.47 | 7.0E-5 | miRNATAP | -0.14 | 3.0E-5 | NA | |
| 8 | hsa-miR-26a-5p | ANKRD52 | -0.13 | 0.44003 | 0.44 | 0.00336 | mirMAP; miRNATAP | -0.19 | 1.0E-5 | NA | |
| 9 | hsa-miR-26a-5p | ARL6IP6 | -0.13 | 0.44003 | 0.14 | 0.36045 | miRNATAP | -0.19 | 1.0E-5 | NA | |
| 10 | hsa-miR-26a-5p | ATAD2 | -0.13 | 0.44003 | 1.58 | 0 | MirTarget | -0.41 | 0 | NA | |
| 11 | hsa-miR-26a-5p | ATAD2B | -0.13 | 0.44003 | 0.61 | 0 | MirTarget; miRNATAP | -0.11 | 0.00236 | NA | |
| 12 | hsa-miR-26a-5p | AURKAIP1 | -0.13 | 0.44003 | 0.63 | 4.0E-5 | miRNAWalker2 validate | -0.16 | 0.00019 | NA | |
| 13 | hsa-miR-26a-5p | AVL9 | -0.13 | 0.44003 | 0.94 | 0 | mirMAP | -0.21 | 0 | NA | |
| 14 | hsa-miR-26a-5p | B3GNT5 | -0.13 | 0.44003 | -0.33 | 0.14374 | MirTarget | -0.24 | 0.00019 | NA | |
| 15 | hsa-miR-26a-5p | BARD1 | -0.13 | 0.44003 | 0.84 | 0.00035 | MirTarget | -0.25 | 0.00017 | NA | |
| 16 | hsa-miR-26a-5p | BRWD3 | -0.13 | 0.44003 | 0.68 | 0.00035 | mirMAP | -0.15 | 0.00584 | NA | |
| 17 | hsa-miR-26a-5p | C16orf87 | -0.13 | 0.44003 | 0.57 | 1.0E-5 | mirMAP | -0.12 | 0.00126 | NA | |
| 18 | hsa-miR-26a-5p | C20orf24 | -0.13 | 0.44003 | 1.14 | 0 | miRNATAP | -0.22 | 3.0E-5 | NA | |
| 19 | hsa-miR-26a-5p | CARM1 | -0.13 | 0.44003 | 0.46 | 1.0E-5 | miRNATAP | -0.16 | 0 | NA | |
| 20 | hsa-miR-26a-5p | CCDC43 | -0.13 | 0.44003 | 0.57 | 0 | miRNAWalker2 validate | -0.13 | 2.0E-5 | NA | |
| 21 | hsa-miR-26a-5p | CCNE1 | -0.13 | 0.44003 | 3 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.7 | 0 | 22094936 | Cell cycle regulation and CCNE1 and CDC2 were the only significant overlapping pathway and genes differentially expressed between tumors with high and low levels of miR-26a and EZH2 respectively; Low mRNA levels of EZH2 CCNE1 and CDC2 and high levels of miR-26a are associated with favorable outcome on tamoxifen |
| 22 | hsa-miR-26a-5p | CCNE2 | -0.13 | 0.44003 | 2.15 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.51 | 0 | 24116110; 21901171 | The loss of miR 26a mediated post transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival; The in vitro and in vivo assays showed that overexpression of miR-26a resulted in cell cycle arrest inhibited cell proliferation and decreased tumor growth which was associated with cyclin E2 downregulation;We also show that enforced expression of miR-26a in AML cells is able to inhibit cell cycle progression by downregulating cyclin E2 expression |
| 23 | hsa-miR-26a-5p | CCNJ | -0.13 | 0.44003 | 0.51 | 0.00036 | miRNATAP | -0.12 | 0.00397 | NA | |
| 24 | hsa-miR-26a-5p | CDC6 | -0.13 | 0.44003 | 3.07 | 0 | miRNAWalker2 validate | -0.73 | 0 | 25100863; 27158389 | Here it is demonstrated that miR26a and miR26b inhibit replication licensing and the proliferation migration and invasion of lung cancer cells by targeting CDC6; The current study suggests that miR26a miR26b and CDC6 and factors regulating their expression represent potential cancer diagnostic and prognostic markers as well as anticancer targets;miR 26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression; Bioinformatics analysis revealed Cdc6 was a target gene of miR-26a; dual-luciferase assay and validation assay showed miR-26a could act on the 3'UTR of Cdc6 to regulate Cdc6 expression; These findings suggest that miR-26a may act on the 3'UTR of Cdc6 to regulate Cdc6 expression which then inhibit the proliferation of ovarian cancer cells and induce their apoptosis |
| 25 | hsa-miR-26a-5p | CDH2 | -0.13 | 0.44003 | 0.21 | 0.68235 | miRNATAP | -0.49 | 0.00061 | NA | |
| 26 | hsa-miR-26a-5p | CDK2AP1 | -0.13 | 0.44003 | 0.32 | 0.01366 | MirTarget; miRNATAP | -0.11 | 0.00207 | NA | |
| 27 | hsa-miR-26a-5p | CDK8 | -0.13 | 0.44003 | 0.3 | 0.03071 | miRNAWalker2 validate | -0.23 | 0 | NA | |
| 28 | hsa-miR-26a-5p | CDR2L | -0.13 | 0.44003 | 0.26 | 0.21768 | miRNATAP | -0.24 | 7.0E-5 | NA | |
| 29 | hsa-miR-26a-5p | CEBPG | -0.13 | 0.44003 | 0.05 | 0.71569 | miRNATAP | -0.11 | 0.00787 | NA | |
| 30 | hsa-miR-26a-5p | CENPP | -0.13 | 0.44003 | 0.51 | 0.00813 | mirMAP | -0.2 | 0.00026 | NA | |
| 31 | hsa-miR-26a-5p | CHAC1 | -0.13 | 0.44003 | 0.96 | 0.00031 | MirTarget; miRNATAP | -0.23 | 0.00294 | NA | |
| 32 | hsa-miR-26a-5p | CHORDC1 | -0.13 | 0.44003 | 0.88 | 0 | MirTarget | -0.25 | 0 | NA | |
| 33 | hsa-miR-26a-5p | CLTC | -0.13 | 0.44003 | 0.44 | 9.0E-5 | miRNATAP | -0.13 | 8.0E-5 | NA | |
| 34 | hsa-miR-26a-5p | CNTD2 | -0.13 | 0.44003 | 3.51 | 0 | miRNAWalker2 validate | -0.46 | 0.00192 | NA | |
| 35 | hsa-miR-26a-5p | COASY | -0.13 | 0.44003 | 0.76 | 0 | miRNAWalker2 validate | -0.21 | 0 | NA | |
| 36 | hsa-miR-26a-5p | COL11A1 | -0.13 | 0.44003 | 5.23 | 0 | miRNATAP | -0.98 | 1.0E-5 | NA | |
| 37 | hsa-miR-26a-5p | COL12A1 | -0.13 | 0.44003 | -0.85 | 0.03497 | miRNATAP | -0.35 | 0.00194 | NA | |
| 38 | hsa-miR-26a-5p | COL1A2 | -0.13 | 0.44003 | 0.88 | 0.00369 | MirTarget; miRNATAP | -0.25 | 0.0032 | NA | |
| 39 | hsa-miR-26a-5p | COL5A1 | -0.13 | 0.44003 | 1.57 | 0 | miRNATAP | -0.29 | 0.00093 | NA | |
| 40 | hsa-miR-26a-5p | COPS7B | -0.13 | 0.44003 | 0.71 | 0 | miRNATAP | -0.17 | 0 | NA | |
| 41 | hsa-miR-26a-5p | CPD | -0.13 | 0.44003 | 0.91 | 9.0E-5 | MirTarget; mirMAP | -0.23 | 0.00063 | NA | |
| 42 | hsa-miR-26a-5p | DCUN1D1 | -0.13 | 0.44003 | 0.14 | 0.30132 | mirMAP | -0.11 | 0.00565 | NA | |
| 43 | hsa-miR-26a-5p | DEPDC1 | -0.13 | 0.44003 | 3.45 | 0 | MirTarget | -0.72 | 0 | NA | |
| 44 | hsa-miR-26a-5p | DEPDC1B | -0.13 | 0.44003 | 3.46 | 0 | MirTarget; miRNATAP | -0.61 | 0 | NA | |
| 45 | hsa-miR-26a-5p | DGCR14 | -0.13 | 0.44003 | 0.17 | 0.14595 | mirMAP; miRNATAP | -0.13 | 5.0E-5 | NA | |
| 46 | hsa-miR-26a-5p | DHX15 | -0.13 | 0.44003 | 0.35 | 0.00047 | miRNAWalker2 validate | -0.11 | 0.00018 | NA | |
| 47 | hsa-miR-26a-5p | DLG5 | -0.13 | 0.44003 | 1.13 | 0 | MirTarget; miRNATAP | -0.26 | 0 | NA | |
| 48 | hsa-miR-26a-5p | DNAJC10 | -0.13 | 0.44003 | 0.8 | 0 | mirMAP | -0.11 | 0.00748 | NA | |
| 49 | hsa-miR-26a-5p | DNMT1 | -0.13 | 0.44003 | 0.72 | 0 | miRNAWalker2 validate | -0.27 | 0 | NA | |
| 50 | hsa-miR-26a-5p | E2F2 | -0.13 | 0.44003 | 2.22 | 0 | miRNATAP | -0.5 | 0 | 26458859 | MiR 26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2; Our results suggest that miR-26a can improve the sensitivity of GC cells to cisplatin-based chemotherapies through targeting NRAS and E2F2 and provide the first evidence of the potential utility of miR-26a as a sensitizer in chemotherapy for GC |
| 51 | hsa-miR-26a-5p | E2F7 | -0.13 | 0.44003 | 2.4 | 0 | miRNAWalker2 validate; miRNATAP | -0.46 | 0 | 23096114 | Here we identify E2F7 as a novel target of miR-26a; Thus these findings indicate that the newly identified miR-26a target E2F7 might have an important role in monocytic differentiation and leukemogenesis |
| 52 | hsa-miR-26a-5p | EIF2AK2 | -0.13 | 0.44003 | 0.62 | 9.0E-5 | mirMAP | -0.14 | 0.00185 | NA | |
| 53 | hsa-miR-26a-5p | ELOVL6 | -0.13 | 0.44003 | 0.82 | 0.02787 | miRNAWalker2 validate | -0.26 | 0.01393 | NA | |
| 54 | hsa-miR-26a-5p | EP400 | -0.13 | 0.44003 | 0.15 | 0.27209 | MirTarget; miRNATAP | -0.11 | 0.00293 | NA | |
| 55 | hsa-miR-26a-5p | EZH2 | -0.13 | 0.44003 | 2.64 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.55 | 0 | 20952513; 23750239; 25611389; 24452597; 26733151; 21901171; 25494962; 27517917; 22086681; 27562865; 22930729; 22094936 | Pathologically decreased miR 26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer; Subsequently MTDH and EZH2 are identified as two direct targets of miR-26a and they are significantly upregulated in breast cancer; MCF7 xenografts with exogenous miR-26a show that a decrease in expression of both MTDH and EZH2 is accompanied by an increase in apoptosis; Our findings suggest that miR-26a functionally antagonizes human breast carcinogenesis by targeting MTDH and EZH2;MiR-26a has been reported as a tumor suppressor microRNA in breast cancer which is attributed mainly to targeting of MTDH and EZH2 however the expression profile and therapeutic potential of miR-26a is still unclear;Significant inverse correlation between EZH2 and hsa-miR-26a-5p R2=0.56 P=0.0001 and hsa-let-7b-5p R2=0.19 P=0.02 expression was observed in the same samples corroborating the belief of EZH2 being a bona fide target for these two miRNAs in CRC;Moreover EZH2 was upregulated and inversely correlated with miR-26a expression in the osteosarcoma tissues; Thus for the first time we provide convincing evidence that downregulation of miR-26a is associated with tumor aggressiveness and tumor metastasis and miR-26a inhibits cell migration and invasion by targeting the EZH2 gene in osteosarcoma;Through down-regulation of EZH2 expression and up-regulation of E-cadherin expression miR-26a inhibited the EMT process in vitro and in vivo; Luciferase reporter assay showed that miR-26a directly interacted with EZH2 messenger RNA mRNA; Furthermore the expression of miR-26a was positively correlated with E-cadherin expression and inversely correlated with EZH2 expression in human HCC tissue; miR-26a inhibited the EMT process in HCC by down-regulating EZH2 expression;Previously EZH2 was shown to be regulated by miR-26a at the translational levels in lymphomas;miR 26a promoted by interferon alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2; Here we report that the IFN-α-induced microRNA-26a miR-26a can inhibit HCC proliferation and invasion by suppressing enhancer of zeste homologue 2 EZH2 expression in tumor cells; It was shown that there was increased miR-26a accompanied with downregulated EZH2 expression in the HCC specimens and EZH2 mRNA levels were inversely correlated with miR-26a expression; In addition the miR-26a mimic transfection decreased the EZH2 expression level significantly in the transfected HepG2 cells and inhibited HepG2 cell proliferation and invasion effectively; Our results indicate that miR-26a exerts growth inhibition in HCC and that its inhibitory effect is mediated briefly by blocking EZH2 expression;miR-26a inhibition partly prevents the metformin viability effect and the PTEN and EZH2 expression reduction;We also found that reexpression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in pancreatic cancer cells;In the present study the influence of miR-26a and miR-138 on EZH2 and cellular function including the impact on the cell cycle regulating network was evaluated in PCa cells; The present findings suggest an anti-proliferative role for miR-26a and miR-138 in PCa by blocking the G1/S-phase transition independent of EZH2 but via a concerted inhibition of crucial cell cycle regulators;We propose the hypermethylation of miR-26a as an alternative pathway of ERG rearrangement-independent EZH2 activation;High miR 26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer; Main objective of the present study is to investigate miR-26a and miR-101 levels which both target EZH2 for their association with molecular pathways and with efficacy of tamoxifen as first-line monotherapy for metastatic breast cancer; Cell cycle regulation and CCNE1 and CDC2 were the only significant overlapping pathway and genes differentially expressed between tumors with high and low levels of miR-26a and EZH2 respectively; Cell cycle regulation is the only overlapping pathway linked to miR-26a and EZH2 levels; Low mRNA levels of EZH2 CCNE1 and CDC2 and high levels of miR-26a are associated with favorable outcome on tamoxifen |
| 56 | hsa-miR-26a-5p | FAM136A | -0.13 | 0.44003 | 1.18 | 0 | MirTarget; miRNATAP | -0.23 | 0 | NA | |
| 57 | hsa-miR-26a-5p | FAM199X | -0.13 | 0.44003 | 0.79 | 0 | mirMAP | -0.15 | 0.00014 | NA | |
| 58 | hsa-miR-26a-5p | FAM49B | -0.13 | 0.44003 | 0.4 | 0.00296 | miRNATAP | -0.12 | 0.00218 | NA | |
| 59 | hsa-miR-26a-5p | FAM98A | -0.13 | 0.44003 | 0.63 | 0 | MirTarget; miRNATAP | -0.16 | 0 | NA | |
| 60 | hsa-miR-26a-5p | FANCA | -0.13 | 0.44003 | 2.06 | 0 | miRNATAP | -0.44 | 0 | NA | |
| 61 | hsa-miR-26a-5p | FANCF | -0.13 | 0.44003 | 0.97 | 0 | MirTarget | -0.11 | 0.0011 | NA | |
| 62 | hsa-miR-26a-5p | FASN | -0.13 | 0.44003 | -0.69 | 0.00939 | miRNAWalker2 validate | -0.27 | 0.00029 | NA | |
| 63 | hsa-miR-26a-5p | FBXL19 | -0.13 | 0.44003 | 1.33 | 0 | miRNATAP | -0.41 | 0 | NA | |
| 64 | hsa-miR-26a-5p | FBXO32 | -0.13 | 0.44003 | 1.92 | 0 | mirMAP | -0.23 | 0.00429 | NA | |
| 65 | hsa-miR-26a-5p | FEN1 | -0.13 | 0.44003 | 1.39 | 0 | MirTarget | -0.36 | 0 | NA | |
| 66 | hsa-miR-26a-5p | FGD1 | -0.13 | 0.44003 | 0.41 | 0.08404 | MirTarget; miRNATAP | -0.33 | 0 | NA | |
| 67 | hsa-miR-26a-5p | FLVCR1 | -0.13 | 0.44003 | 1.37 | 0 | MirTarget; miRNATAP | -0.17 | 0.00296 | NA | |
| 68 | hsa-miR-26a-5p | GDAP1 | -0.13 | 0.44003 | 0.1 | 0.63942 | miRNAWalker2 validate; miRTarBase | -0.16 | 0.00975 | NA | |
| 69 | hsa-miR-26a-5p | GJC1 | -0.13 | 0.44003 | -0.59 | 0.01598 | mirMAP | -0.17 | 0.01664 | NA | |
| 70 | hsa-miR-26a-5p | GMPS | -0.13 | 0.44003 | 0.62 | 4.0E-5 | mirMAP | -0.21 | 0 | NA | |
| 71 | hsa-miR-26a-5p | GRB10 | -0.13 | 0.44003 | 0.16 | 0.47679 | MirTarget | -0.17 | 0.00895 | NA | |
| 72 | hsa-miR-26a-5p | GTF3C2 | -0.13 | 0.44003 | 0.51 | 0 | miRNATAP | -0.17 | 0 | NA | |
| 73 | hsa-miR-26a-5p | HAPLN1 | -0.13 | 0.44003 | -0.22 | 0.68151 | MirTarget; miRNATAP | -0.45 | 0.00333 | NA | |
| 74 | hsa-miR-26a-5p | HIST1H4J | -0.13 | 0.44003 | 1.33 | 0 | miRNAWalker2 validate | -0.29 | 0.00018 | NA | |
| 75 | hsa-miR-26a-5p | HIST2H2AA3 | -0.13 | 0.44003 | 1.74 | 0 | miRNAWalker2 validate | -0.27 | 0.00283 | NA | |
| 76 | hsa-miR-26a-5p | HMGA1 | -0.13 | 0.44003 | 1.93 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.44 | 0 | 25455159; 25755724; 23796420; 22245693 | Prognostic value of miR 26a and HMGA1 in urothelial bladder cancer; MicroRNA-26a miR-26a functions as a tumor suppressor by regulating its direct target gene high mobility group AT-hook 1 HMGA1; This study was aimed to investigate the associations of differential expression of miR-26a and HMGA1 with tumor progression and prognosis in urothelial bladder cancer UBC patients; One hundred and twenty-six UBC patients were selected and quantitative real-time PCR was performed to detect the expression of miR-26a and HMGA1 mRNA in the respective tumors; Our data showed the decreased expression of miR-26a and the increased expression of HMGA1 mRNA in UBC tissues compared with corresponding non-cancerous tissues both P<0.001; Then the expression levels of miR-26a in UBC tissues were negatively correlated with those of HMGA1 mRNA significantly r=-0.72 P<0.001; In addition UBC patients with combined miR-26a downregulation and HMGA1 upregulation miR-26a-low/HMGA1-high more frequently had advanced pathological stage P<0.001 and high tumor grade P<0.001; Interaction between miR-26a and its target gene HMGA1 may contribute to the malignant progression of human UBC; Tumors with miR-26a downregulation in combination with high expression of HMGA1 showed a worse prognosis than the other tumors;To investigate the crucial role of miR-26a in breast cancer and to validate whether miR-26a could regulate proliferation of breast cancer cells by targeting high mobility group AT-hook 1 HMGA1; The luciferase activity was significantly decreased after co-transfection with psiCHECK-2/HMGA1 3'-UTR and miR-26a mimics in comparison with control cells and qRT-PCR and Western blotting analysis found that HMGA1 expression at the mRNA and protein levels decreased in the miR-26a mimic-treatment group relative to NC; MTT assay showed that down regulation of HMGA1 by siRNA could significantly enhance the tumor-suppressive effect of miR-26a P < 0.05; The results of the present study indicate that miR-26a may be associated with human breast carcinogenesis which inhibits tumor cell proliferation by targeting HMGA1;miR 26a inhibits proliferation and motility in bladder cancer by targeting HMGA1; High mobility group AT-hook 1 HMGA1 a gene that modulates cell cycle transition and cell motility was verified as a novel target of miR-26a in bladder cancer;HMGA1 was proved to be a target of miR-26a by Luciferase reporter assay Real-time PCR and Western-blotting; Furthermore we demonstrated that HMGA1 an oncogene is a direct target of miR-26a; Nude mice xenograft models confirmed that metformin up-regulated the level of miR-26a and surpressed the expression of HMGA1 in vivo |
| 77 | hsa-miR-26a-5p | HMGB3 | -0.13 | 0.44003 | 2.91 | 0 | mirMAP | -0.29 | 0.00417 | NA | |
| 78 | hsa-miR-26a-5p | HOXD13 | -0.13 | 0.44003 | 1.14 | 0.07153 | miRNATAP | -0.5 | 0.00557 | NA | |
| 79 | hsa-miR-26a-5p | HS6ST1 | -0.13 | 0.44003 | 0.04 | 0.8014 | miRNATAP | -0.1 | 0.04425 | NA | |
| 80 | hsa-miR-26a-5p | HSPA13 | -0.13 | 0.44003 | 0.07 | 0.6719 | miRNATAP | -0.11 | 0.01015 | NA | |
| 81 | hsa-miR-26a-5p | HSPA8 | -0.13 | 0.44003 | 0.06 | 0.68869 | miRNAWalker2 validate | -0.11 | 0.00476 | NA | |
| 82 | hsa-miR-26a-5p | HUWE1 | -0.13 | 0.44003 | 0.24 | 0.07152 | miRNATAP | -0.11 | 0.00591 | NA | |
| 83 | hsa-miR-26a-5p | ITGA5 | -0.13 | 0.44003 | -1.01 | 1.0E-5 | miRNATAP | -0.2 | 0.00169 | 25537511 | Furthermore we provide experimental evidence to confirm that ITGA5 is a bona fide target of miR-26a |
| 84 | hsa-miR-26a-5p | ITSN1 | -0.13 | 0.44003 | -0.28 | 0.03525 | mirMAP | -0.1 | 0.00613 | NA | |
| 85 | hsa-miR-26a-5p | KCMF1 | -0.13 | 0.44003 | 0.27 | 0.00636 | miRNATAP | -0.11 | 7.0E-5 | NA | |
| 86 | hsa-miR-26a-5p | KCTD5 | -0.13 | 0.44003 | 0.56 | 3.0E-5 | miRNAWalker2 validate | -0.12 | 0.0018 | NA | |
| 87 | hsa-miR-26a-5p | KIAA1147 | -0.13 | 0.44003 | -0.2 | 0.18406 | mirMAP | -0.1 | 0.01657 | NA | |
| 88 | hsa-miR-26a-5p | KPNA1 | -0.13 | 0.44003 | 0.08 | 0.4478 | mirMAP | -0.12 | 5.0E-5 | NA | |
| 89 | hsa-miR-26a-5p | KPNA2 | -0.13 | 0.44003 | 1.69 | 0 | MirTarget | -0.5 | 0 | NA | |
| 90 | hsa-miR-26a-5p | LARP1 | -0.13 | 0.44003 | 0.42 | 0.0011 | miRNATAP | -0.15 | 7.0E-5 | 26063484 | Gene expression data and in silico analysis showed that the gene encoding La-related protein 1 LARP1 was a putative candidate of miR-26a and miR-26b regulation; Moreover luciferase reporter assays revealed that LARP1 was a direct target of both miR-26a and miR-26b; Our present data suggested that loss of tumor-suppressive miR-26a and miR-26b enhanced cancer cell invasion in PCa through direct regulation of oncogenic LARP1 |
| 91 | hsa-miR-26a-5p | LINGO1 | -0.13 | 0.44003 | 1.64 | 1.0E-5 | miRNATAP | -0.21 | 0.03989 | NA | |
| 92 | hsa-miR-26a-5p | LPGAT1 | -0.13 | 0.44003 | 0.97 | 0 | mirMAP | -0.11 | 0.01203 | NA | |
| 93 | hsa-miR-26a-5p | LSM12 | -0.13 | 0.44003 | 0.63 | 0 | MirTarget; miRNATAP | -0.12 | 0.00022 | NA | |
| 94 | hsa-miR-26a-5p | MAEA | -0.13 | 0.44003 | 0.36 | 0.00035 | MirTarget | -0.12 | 3.0E-5 | NA | |
| 95 | hsa-miR-26a-5p | MAP2 | -0.13 | 0.44003 | -1.2 | 0.0009 | MirTarget; miRNATAP | -0.2 | 0.04827 | NA | |
| 96 | hsa-miR-26a-5p | MAP7 | -0.13 | 0.44003 | 0.44 | 0.01067 | MirTarget | -0.13 | 0.00857 | NA | |
| 97 | hsa-miR-26a-5p | MAPK6 | -0.13 | 0.44003 | 0.44 | 0.00512 | MirTarget | -0.23 | 0 | NA | |
| 98 | hsa-miR-26a-5p | MEX3B | -0.13 | 0.44003 | 0.96 | 0 | miRNATAP | -0.22 | 8.0E-5 | NA | |
| 99 | hsa-miR-26a-5p | MLEC | -0.13 | 0.44003 | 0.38 | 0.01545 | miRNATAP | -0.12 | 0.00545 | NA | |
| 100 | hsa-miR-26a-5p | MMP14 | -0.13 | 0.44003 | 0.85 | 0.00021 | miRNATAP | -0.24 | 0.00031 | NA | |
| 101 | hsa-miR-26a-5p | MRPL35 | -0.13 | 0.44003 | 0.42 | 2.0E-5 | mirMAP | -0.11 | 0.00012 | NA | |
| 102 | hsa-miR-26a-5p | MRPL51 | -0.13 | 0.44003 | 0.5 | 9.0E-5 | miRNAWalker2 validate | -0.13 | 0.00044 | NA | |
| 103 | hsa-miR-26a-5p | MSH6 | -0.13 | 0.44003 | 0.6 | 2.0E-5 | miRNAWalker2 validate | -0.21 | 0 | NA | |
| 104 | hsa-miR-26a-5p | MTHFD2 | -0.13 | 0.44003 | 1.38 | 0 | mirMAP | -0.35 | 0 | NA | |
| 105 | hsa-miR-26a-5p | MTX2 | -0.13 | 0.44003 | 0.83 | 0 | MirTarget; miRNATAP | -0.11 | 0.00155 | NA | |
| 106 | hsa-miR-26a-5p | NAA15 | -0.13 | 0.44003 | 0.43 | 0.00049 | MirTarget; miRNATAP | -0.16 | 0 | NA | |
| 107 | hsa-miR-26a-5p | NACC2 | -0.13 | 0.44003 | -0.77 | 0.0001 | mirMAP; miRNATAP | -0.13 | 0.02003 | NA | |
| 108 | hsa-miR-26a-5p | NAMPT | -0.13 | 0.44003 | 0.03 | 0.92171 | miRNATAP | -0.21 | 0.00501 | NA | |
| 109 | hsa-miR-26a-5p | NAV1 | -0.13 | 0.44003 | 0.64 | 0.00272 | mirMAP | -0.17 | 0.00484 | NA | |
| 110 | hsa-miR-26a-5p | NLK | -0.13 | 0.44003 | 0.2 | 0.05358 | miRNATAP | -0.11 | 0.00016 | NA | |
| 111 | hsa-miR-26a-5p | NPLOC4 | -0.13 | 0.44003 | 0.62 | 0 | mirMAP | -0.19 | 0 | NA | |
| 112 | hsa-miR-26a-5p | NT5DC3 | -0.13 | 0.44003 | 0.69 | 0.00025 | mirMAP | -0.24 | 1.0E-5 | NA | |
| 113 | hsa-miR-26a-5p | NUP153 | -0.13 | 0.44003 | 0.05 | 0.69557 | miRNATAP | -0.12 | 0.00074 | NA | |
| 114 | hsa-miR-26a-5p | NUP155 | -0.13 | 0.44003 | 1.06 | 0 | mirMAP | -0.29 | 0 | NA | |
| 115 | hsa-miR-26a-5p | NUP205 | -0.13 | 0.44003 | 0.48 | 0.0007 | miRNAWalker2 validate | -0.26 | 0 | NA | |
| 116 | hsa-miR-26a-5p | OLA1 | -0.13 | 0.44003 | 0.82 | 0 | miRNAWalker2 validate | -0.14 | 0.00021 | NA | |
| 117 | hsa-miR-26a-5p | OTUD6B | -0.13 | 0.44003 | 0.28 | 0.07463 | MirTarget | -0.16 | 0.00029 | NA | |
| 118 | hsa-miR-26a-5p | PAWR | -0.13 | 0.44003 | 0.41 | 0.00957 | MirTarget; mirMAP | -0.27 | 0 | NA | |
| 119 | hsa-miR-26a-5p | PCCB | -0.13 | 0.44003 | 0.27 | 0.02157 | mirMAP | -0.11 | 0.00049 | NA | |
| 120 | hsa-miR-26a-5p | PCYT1A | -0.13 | 0.44003 | -0.13 | 0.28392 | miRNAWalker2 validate | -0.13 | 0.00028 | NA | |
| 121 | hsa-miR-26a-5p | PGM2 | -0.13 | 0.44003 | -0.05 | 0.77499 | MirTarget | -0.16 | 0.00106 | NA | |
| 122 | hsa-miR-26a-5p | PGM2L1 | -0.13 | 0.44003 | 1.7 | 0 | miRNATAP | -0.22 | 0.00038 | NA | |
| 123 | hsa-miR-26a-5p | PHF6 | -0.13 | 0.44003 | 0.64 | 0 | MirTarget; mirMAP; miRNATAP | -0.13 | 0.00036 | NA | |
| 124 | hsa-miR-26a-5p | PHTF2 | -0.13 | 0.44003 | 0.57 | 0.00012 | MirTarget; miRNATAP | -0.16 | 0.00011 | NA | |
| 125 | hsa-miR-26a-5p | PI15 | -0.13 | 0.44003 | 0.84 | 0.04202 | mirMAP | -0.27 | 0.02157 | NA | |
| 126 | hsa-miR-26a-5p | PITPNC1 | -0.13 | 0.44003 | 0.36 | 0.14945 | MirTarget; miRNATAP | -0.26 | 0.00024 | NA | |
| 127 | hsa-miR-26a-5p | PLEKHH1 | -0.13 | 0.44003 | 0.35 | 0.36129 | miRNATAP | -0.24 | 0.02669 | NA | |
| 128 | hsa-miR-26a-5p | PLOD2 | -0.13 | 0.44003 | 1.28 | 7.0E-5 | MirTarget; miRNATAP | -0.47 | 0 | 26983694; 27310702 | Thus our data showed that two genes promoting metastasis LOXL2 and PLOD2 were epigenetically regulated by tumor-suppressive microRNAs miR-26a and miR-26b providing important insights into the molecular mechanisms of RCC metastasis;The gene encoding procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 PLOD2 a collagen crosslinking enzyme was directly regulated by miR-26a-5p and miR-26b-5p; PLOD2 which is associated with the stiffness of the extracellular matrix was directly regulated by miR-26a-5p and miR-26b-5p and may be a good prognostic marker in patients with BC |
| 129 | hsa-miR-26a-5p | POLR3G | -0.13 | 0.44003 | 0.68 | 0.00521 | MirTarget | -0.35 | 0 | NA | |
| 130 | hsa-miR-26a-5p | POM121 | -0.13 | 0.44003 | 0.18 | 0.10955 | mirMAP | -0.12 | 0.00014 | NA | |
| 131 | hsa-miR-26a-5p | PPIA | -0.13 | 0.44003 | 0.45 | 0.00059 | miRNAWalker2 validate | -0.12 | 0.00121 | NA | |
| 132 | hsa-miR-26a-5p | PPP1CC | -0.13 | 0.44003 | 0.15 | 0.17274 | miRNAWalker2 validate | -0.1 | 0.00079 | NA | |
| 133 | hsa-miR-26a-5p | PTDSS1 | -0.13 | 0.44003 | 0.01 | 0.90464 | mirMAP | -0.14 | 3.0E-5 | NA | |
| 134 | hsa-miR-26a-5p | PTTG1 | -0.13 | 0.44003 | 2.3 | 0 | miRNAWalker2 validate | -0.4 | 0 | NA | |
| 135 | hsa-miR-26a-5p | RAB3B | -0.13 | 0.44003 | 2.33 | 8.0E-5 | mirMAP | -0.76 | 1.0E-5 | NA | |
| 136 | hsa-miR-26a-5p | RAB6B | -0.13 | 0.44003 | 0.43 | 0.1203 | mirMAP | -0.21 | 0.00692 | NA | |
| 137 | hsa-miR-26a-5p | REEP4 | -0.13 | 0.44003 | 0.32 | 0.01501 | MirTarget; miRNATAP | -0.18 | 0 | NA | |
| 138 | hsa-miR-26a-5p | RFFL | -0.13 | 0.44003 | 0.43 | 0.00056 | mirMAP | -0.14 | 5.0E-5 | NA | |
| 139 | hsa-miR-26a-5p | RGS4 | -0.13 | 0.44003 | 0.2 | 0.56422 | MirTarget; miRNATAP | -0.23 | 0.02047 | NA | |
| 140 | hsa-miR-26a-5p | RRM2 | -0.13 | 0.44003 | 2.87 | 0 | miRNAWalker2 validate | -0.68 | 0 | NA | |
| 141 | hsa-miR-26a-5p | RRP7A | -0.13 | 0.44003 | 0.38 | 0.01057 | mirMAP | -0.16 | 9.0E-5 | NA | |
| 142 | hsa-miR-26a-5p | SACS | -0.13 | 0.44003 | 0.27 | 0.12103 | MirTarget; miRNATAP | -0.13 | 0.00839 | NA | |
| 143 | hsa-miR-26a-5p | SAMD8 | -0.13 | 0.44003 | -0.2 | 0.17739 | MirTarget; miRNATAP | -0.11 | 0.00681 | NA | |
| 144 | hsa-miR-26a-5p | SBNO1 | -0.13 | 0.44003 | 0.22 | 0.25959 | mirMAP; miRNATAP | -0.2 | 0.00028 | NA | |
| 145 | hsa-miR-26a-5p | SENP5 | -0.13 | 0.44003 | 0.17 | 0.11299 | MirTarget; miRNATAP | -0.13 | 3.0E-5 | NA | |
| 146 | hsa-miR-26a-5p | SERBP1 | -0.13 | 0.44003 | 0.23 | 0.01799 | miRNAWalker2 validate; miRTarBase; MirTarget; mirMAP; miRNATAP | -0.12 | 3.0E-5 | 27449037 | Loss of miR 26a 5p promotes proliferation migration and invasion in prostate cancer through negatively regulating SERBP1; Using bioinformatics analysis we found that serpine1 messenger RNA mRNA binding protein 1 SERBP1 was a potential downstream target of miR-26a-5p; Using luciferase reporter and western blot we identified that miR-26a-5p negatively regulated SERBP1 on the PC cell line level; Additionally SERBP1 was identified as a downstream target of miR-26a-5p; Taken together our results for the first time demonstrate that the loss of miR-26a-5p promotes proliferation migration and invasion through targeting SERBP1 in PC supporting the tumor-suppressing role of miR-26a-5p in PC |
| 147 | hsa-miR-26a-5p | SFPQ | -0.13 | 0.44003 | 0.4 | 1.0E-5 | MirTarget | -0.1 | 0.0001 | NA | |
| 148 | hsa-miR-26a-5p | SFXN1 | -0.13 | 0.44003 | 1.45 | 0 | MirTarget | -0.25 | 0 | NA | |
| 149 | hsa-miR-26a-5p | SH3BP2 | -0.13 | 0.44003 | -0.18 | 0.19643 | mirMAP | -0.13 | 0.00099 | NA | |
| 150 | hsa-miR-26a-5p | SKP2 | -0.13 | 0.44003 | 0.72 | 0.00194 | MirTarget | -0.34 | 0 | NA |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | DNA METABOLIC PROCESS | 26 | 758 | 2.549e-08 | 0.0001186 |
| 2 | REGULATION OF CHROMATIN SILENCING | 5 | 21 | 1.5e-06 | 0.00349 |
| 3 | MULTI ORGANISM TRANSPORT | 7 | 68 | 4.41e-06 | 0.00513 |
| 4 | MULTI ORGANISM LOCALIZATION | 7 | 68 | 4.41e-06 | 0.00513 |
| 5 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 20 | 662 | 7.891e-06 | 0.00612 |
| 6 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 20 | 662 | 7.891e-06 | 0.00612 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | ENZYME BINDING | 40 | 1737 | 2.364e-07 | 0.0002196 |
| 2 | MACROMOLECULAR COMPLEX BINDING | 31 | 1399 | 1.449e-05 | 0.006733 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | NUCLEAR PORE | 7 | 77 | 1.016e-05 | 0.005934 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | Cell_cycle_hsa04110 | 6 | 124 | 0.001371 | 0.07128 | |
| 2 | Cellular_senescence_hsa04218 | 5 | 160 | 0.02043 | 0.3466 | |
| 3 | p53_signaling_pathway_hsa04115 | 3 | 68 | 0.0288 | 0.3466 | |
| 4 | Oocyte_meiosis_hsa04114 | 4 | 124 | 0.0333 | 0.3466 | |
| 5 | Adherens_junction_hsa04520 | 3 | 72 | 0.03332 | 0.3466 | |
| 6 | Ferroptosis_hsa04216 | 2 | 40 | 0.05793 | 0.5021 | |
| 7 | Necroptosis_hsa04217 | 4 | 164 | 0.07693 | 0.5715 | |
| 8 | FoxO_signaling_pathway_hsa04068 | 3 | 132 | 0.1386 | 0.9006 | |
| 9 | mTOR_signaling_pathway_hsa04150 | 3 | 151 | 0.1831 | 0.9907 | |
| 10 | ECM_receptor_interaction_hsa04512 | 2 | 82 | 0.1905 | 0.9907 | |
| 11 | Focal_adhesion_hsa04510 | 3 | 199 | 0.307 | 1 | |
| 12 | AMPK_signaling_pathway_hsa04152 | 2 | 121 | 0.3305 | 1 | |
| 13 | Regulation_of_actin_cytoskeleton_hsa04810 | 3 | 208 | 0.331 | 1 | |
| 14 | Lysosome_hsa04142 | 2 | 123 | 0.3377 | 1 | |
| 15 | Wnt_signaling_pathway_hsa04310 | 2 | 146 | 0.4175 | 1 | |
| 16 | PI3K_Akt_signaling_pathway_hsa04151 | 4 | 352 | 0.4499 | 1 | |
| 17 | cGMP_PKG_signaling_pathway_hsa04022 | 2 | 163 | 0.4733 | 1 | |
| 18 | MAPK_signaling_pathway_hsa04010 | 3 | 295 | 0.551 | 1 | |
| 19 | Endocytosis_hsa04144 | 2 | 244 | 0.6903 | 1 |
